Marksans Pharma receives EIR from USFDA for Time-Cap Labs facility
By Aman Shukla Published on June 30, 2025, 12:33 IST
Marksans Pharma has announced a positive update regarding its US operations. The company shared that its wholly owned subsidiary, Time-Cap Laboratories Inc., based in Farmingdale, New York, has successfully received the Establishment Inspection Report (EIR) from the USFDA.
This follows a routine cGMP (current Good Manufacturing Practices) inspection that took place from April 16 to April 24, 2025. The inspection covered the site's compliance with quality standards, and the EIR indicates a satisfactory outcome.
For those unfamiliar, Marksans Pharma is a Mumbai-headquartered pharmaceutical company that specializes in research, manufacturing, and global marketing of generic medicines. Its facilities are approved by top global regulators like the USFDA, UKMHRA, and Australia's TGA.
The company's product lineup spans key therapeutic areas, including cardiovascular, central nervous system, diabetes care, pain relief, gastrointestinal health, and allergy treatment—and it's actively selling these in markets around the world.
This USFDA approval reinforces Marksans Pharma's commitment to maintaining high-quality standards and its steady expansion in regulated markets.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at BusinessUpturn.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Engadget
26 minutes ago
- Engadget
Cloudflare experiment will block AI bot scrapers unless they pay a fee
Cloudflare has rolled out a couple of new measures meant to keep AI bot crawlers at bay. To start with, every new domain customer that signs up with the company to manage their website traffic will now be asked if they want to allow AI crawlers or to block them altogether. The company released a free tool in 2024 to block AI bots, but with this change, users can block them by default without having to tinker with their settings. Several big publishers, including Condé Nast, TIME and The Associated Press have already signed up to block crawlers. In addition, Cloudflare has launched a private beta experiment called "pay per crawl," which would only allow crawlers to access a website's content if they pay for it. Matthew Prince, Cloudflare's CEO, recently went on record to say that publishers are facing an existential threat, because people aren't clicking on chatbots' source links. If users don't visit those sources, the websites don't get the ad revenue they need to be able to keep running. "Original content is what makes the Internet one of the greatest inventions in the last century, and it's essential that creators continue making it," Prince said in a statement released with the company's latest updates. "AI crawlers have been scraping content without limits. Our goal is to put the power back in the hands of creators, while still helping AI companies innovate. This is about safeguarding the future of a free and vibrant Internet with a new model that works for everyone." Cloudflare believes publishers should be able to charge AI bots for access if they want to, and pay per crawl is its first experiment for that particular purpose. "Each time an AI crawler requests content, they either present payment intent via request headers for successful access (HTTP response code 200), or receive a 402 Payment Required response with pricing," Cloudflare explained. The company records those transactions and provides the underlying technical infrastructure. Publishers will be able to allow certain crawlers to access their content for free if they want to, and they can define a flat, per-request price across its websites for other crawlers. The company says pay per crawl is still in its very early stages, and it expects the tool to evolve in the future. It also says that it supports the development of other marketplaces and ways to charge AI crawlers for content. A marketplace could, for instance, allow dynamic pricing that enable publishers to charge different rates for different types of content.
Yahoo
an hour ago
- Yahoo
Rupee gains alongside Asian peers as US policy worries trouble dollar
By Jaspreet Kalra MUMBAI (Reuters) - The Indian rupee strengthened on Tuesday, alongside most Asian peers, as worries over U.S. President Donald Trump's fiscal policies and uncertainty around trade deals kept the dollar pinned at a more than three-year low against major peers. The rupee closed at 85.52 per U.S. dollar, up about 0.3% on the day. While the rupee strengthened on the day, it was unable to hold onto gains above the 85.50 mark, with traders pointing to bids from a large state-run bank and a few local private banks. The currency is likely to stay rangebound in the near term unless it convincingly breaches either 85.45-85.50 on the upside or 86 on the downside, a trader at a private bank said. Asian currencies were mostly up between 0.1% and 0.4%, while the dollar index declined 0.3% to 96.37, its lowest level since February 2022. Worries about U.S. fiscal policies, uncertainty over trade deals ahead of a looming deadline and concerns over the future independence of the Federal Reserve have all hurt the dollar this year. The dollar index is nursing losses of 11% on the year so far. "The dented safe-haven status of the U.S. amid demanding asset price valuations portends a redistribution of global portfolio flows across various regions. Asia can both drive and benefit from this redistribution," ANZ said in a Tuesday note. While countries with sizeable external investment surpluses, such as Taiwan and South Korea, will lead the diversification from U.S. assets, potential inflows will also extend more broadly to economies like India and Indonesia, the note added. With investors also ramping up wagers on faster rate cuts by the Fed this year, the focus will turn to U.S. economic data due later in the day. Remarks from Fed Chair Jerome Powell will also be in the spotlight for cues on the future path of policy rates. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Upturn
2 hours ago
- Business Upturn
Lupin carves out LupinLife into separate consumer healthcare subsidiary to focus on OTC consumer wellness market
By Aman Shukla Published on July 1, 2025, 15:28 IST Global pharma leader Lupin Limited has announced a major strategic shift by carving out its consumer healthcare arm, LupinLife Consumer Healthcare Ltd. (LCH), into a wholly owned subsidiary, effective today. The move is aimed at creating a focused, agile entity to tap into India's fast-evolving self-care and over-the-counter (OTC) health product space. LupinLife, launched in 2017, has built a strong footprint in the OTC segment with a science-backed product portfolio that includes well-known brands like Softovac®, Beplex Forte®, Corcium®, and Aptivate®. With this restructuring, Lupin is doubling down on its ambitions to strengthen consumer health offerings and deepen its reach in one of the world's most dynamic wellness markets. The newly carved-out company will be led by Anil Kaushal, who steps in as Chief Executive Officer. Under his leadership, the focus will be on unlocking new growth opportunities, expanding market presence, and scaling investments to drive stronger consumer connect and innovation. Nilesh Gupta, Managing Director, Lupin, stated, 'This strategic move reinforces our mission of developing high-impact businesses that drive sustained value. LCH exemplifies our unwavering dedication to patient-centric care and service to consumers.' Ahmedabad Plane Crash Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
